Helix BioMedix Inc. (HXBM)

Overview

Helix BioMedix, Inc. is a pioneering firm in the field of dermatology and consumer products related to skin health, operating predominantly within the United States. Founded in 1988 and based in Bothell, Washington, the company has carved a niche for itself by focusing on the development and commercialization of bioactive peptides. These peptides have applications across a variety of treatments including anti-infective, anti-fungal, and anti-inflammatory areas, specifically targeting skin and wound infections and the prevention of staphylococcus aureus infections. By out-licensing its proprietary peptides to various entities, Helix BioMedix has expanded its reach and influence in the dermatological and skin health sectors.

Products and Services

• Anti-infective Peptides:

Helix BioMedix develops peptides with anti-infective properties aimed at treating skin and wound infections. These products target the eradication of pathogenic microorganisms responsible for infections, promoting faster healing and recovery.

• Anti-fungal Peptides:

Designed to combat fungal infections on the skin, these peptides offer an innovative approach to addressing common but challenging conditions such as athlete's foot and ringworm, offering patients relief and protection against the recurrence of infection.

• Anti-inflammatory Peptides:

With a focus on reducing inflammation and aiding in the healing of skin conditions, these peptides cater to a wide range of dermatological needs, from minor irritations and redness to more severe inflammatory conditions.

• Prevention of Staphylococcus Aureus Infections:

Helix BioMedix has developed specific peptides that help prevent infections caused by Staphylococcus aureus, a common but potentially dangerous bacterium that can reside on the skin. This preventive approach is crucial in healthcare settings and for individuals with compromised skin integrity.

• Out-licensing of Proprietary Peptides:

In addition to developing its own product lineup, Helix BioMedix extends its impact in the dermatological and skin health sector by out-licensing its proprietary peptides to other entities. This strategy enables the broader application and reach of its innovative peptide technology in various product formulations and markets.